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Abstract 
Diabetes mellitus is associated with a reduced responsiveness to 
catecholamines. The reduced responsiveness may be attributable to a 
reduction in beta-adrenoceptor sensitivity to catecholamines. 
Radioligand binding studies demonstrate that chemically-induced diabe-
tes reduces beta-adrenoceptor number without altering beta-
adrenoceptor drug binding affinities. The present study re-examines 
the effect of chronic (10 weeks) streptozotocin-induced diabetes in 
the rat on beta-adrenoceptor drug binding affinity, using phar-
macological techniques, to test the results of the binding studies. 
The study employed two different methods: partial irreversible recep-
tor blockade and the use of a partial agonist, to determine beta-
adrenoceptor agonist binding affinity and the method of competitive 
antagonism to determine beta-adrenoceptor antagonist binding affinity. 
Diabetes produced no significant differences in the dissociation 
constants (l/affinity) for isoproterenol or for metaproterenol and no 
significant differences in the pAz values for timolol maleate which 
correlates to antagonist binding affinity. Therefore, the study con-
firms the results of radioligand binding studies by using intact 
tissue that diabetes does not alter beta-adrenoceptor drug binding 
affinity in cardiac tissue. 
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Diabetes mellitus is associated with a higher incidence of mor-
bidity and mortality from cardiac disease than is present in the non-
diabetic population (Kannel, 1979). The data suggest that diabetes is 
another discrete cause of congestive heart failure and that a car-
diomyopathy is associated with diabetes, as a result of small vessel 
disease, metabolic disorders, or both. These disorders produce struc-
tural, functional, and biochemical changes in cardiac tissue (Ledet et 
al., 1979). 
Vascular disease associated with diabetes mellitus is well known 
(Colwell~ al., 1979; Zoneraich ~al., 1980). However, diabetes may 
produce a cardiopathy which is independent of vascular abnormalities. 
In some cases, pathological studies of diabetic human hearts revealed 
patent and atherosclerosis-free large coronary arteries (Hamby ~al, 
1974). Autopsies failed to detect significant obstructive disease of 
the proximal arteries in some diabetic patients succumbing to heart 
failure (Regan~ al., 1977). Several experimental studies (Regan~ 
al., 1974; Miller, 1979; Fein~ al., 1980; Penpargkul et al., 1980; 
Vadlamudi et al., 1982) demonstrated impaired muscle function in both 
chronic (greater than two weeks duration) and acute (usually less than 
one week) chemically-induced diabetic rat hearts. Some of these stu-
dies, also, suggest that diabetes decreases diastolic ventricular 
compliance and the rate of relaxation (Regan :=..t al., 1974; Miller, 
1979). Streptozotocin-induced diabetes in the rat produces no signifi-
cant cardiac macrovascular disease (Chobanian ~al., 1982), but impairs 
cardiac performance (Vadlamudi et al., 1982). These results suggest 
that diabetes produces a direct alteration of the rat myocardium. 
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A possible consequence of diabetic cardiopathy might be the 
appearance of an ~ltered sensitivity to the positive chronotropic and 
positive inotropic effects of catecholamines (Cavaliere et al., 1980). 
Experimental and clinical evidence suggests that diabetes may also 
alter autonomic control of the myocardium. Clinically, diabetic 
patients exhibit a supersensitivity to cholinomimetic agents and to 
catecholamines; the supersensitivity to the former is more pronounced 
than to the latter (Lloyd-Mostyn and Watkins, 1975). However, hearts 
of two week streptozotocin-diabetic rats are subsensitive to both ace-
tylcholine and catecholamines (Foy and Lucas, 1978). Diabetic hearts 
are less sensitive than non-diabetic hearts to carbachol 100 days 
after . the induction of diabetes by streptozotocin, but they are super-
sensitive to carbachol at 180 days (Vadlamudi and McNeill, 1983). The 
supersensitivity observed both clinically and experimentally may be 
related to the well known autonomic neuropathy associated with chronic 
diabetes in humans (Watkins and Edmonds, 1983) and experimentally 
diabetic rats (Schmidt~ al., 1981). The possible mechanism for 
diabetes-induced cardiac subsensitivity is less clearly defined. 
The effect of diabetes on cardiac responsiveness to catecholami-
nes may vary with the severity of the diabetic state, although the 
evidence is not at all clear. In humans, tachycardia is often asso-
ciated with chronic diabetes, primarily due to vagal dysfunction 
(Lloyd-Mostyn and Watkins, 1975). In the rat, experimental chronic 
diabetes most often produces bradycardia (Savarese and Berkowitz, 
1980), but acute diabetes has no effect on heart rate. A reduction 
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in beta-adrenoceptor sensitivity to catecholamines can explain the 
lowered heart rate of the diabetic rat. ~-adrenoceptor number or 
density and drug-binding affinity determine beta-adrenoceptor sen-
sitivity to catecholamines. Radioligand binding techniques provide a 
method of assessing beta-adrenoceptor density (Bmax) and drug-binding 
affinity. Diabetes produced a 28% decrease in beta-adrenoceptor den-
sity accompanied a 24% in heart rate without any alterations in anta-
gonist (H3-dihydroalprenolol) binding affinity (Savarese and 
Berkowitz, 1980). 
Ingebretson ~al. (198la), Heyliger~ al.(1982), and 
Ramanadham and Tenner (1983) confirm that diabetes decreased beta-
adrenoceptor density without altering antagonist affinity in rat 
hearts. No direct in vitro studies of the positive chronotropic 
responsiveness of diabetic hearts to catecholamines have been per-
formed. Diabetes had no effect on competitive [3H]-DHA binding curves 
by isoproterenol in membrane homogenates suggesting that agonist 
binding affinity is unaltered (Williams~ al., 1983). However, no 
studies on beta-adrenoceptor drug-binding affinities of intact tissue 
have been performed. 
Diabetes alters the mechanical function of the heart, as pre-
viously indicated, but apparently not the inotropic responsiveness to 
catecholamines. Ingebretson ~al. (198lb) reported that acute 
alloxan diabetes had no effect on the inotropic response of isolated 
rat hearts to isoproterenol. Heyliger ~ al. (1982) report that 
diabetic papillary muscle exhibited a decreased ability to respond to 
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beta-adrenergic stimulation, based upon the rates of tension develop-
ment (positive dF/dt) and relaxation (negative dF/dt). In control 
preparations, isoproterenol produced marked increases in both the 
positive dF/dt and negative dF/dt, whereas, in diabetic preparations, 
the positive dF/dt was unresponsive to isoproterenol and the negative 
dF/dt responded only marginally. 
The questions of cardiac beta-adrenoceptor sensitivity in experi-
mental diabetes has not been fully resolved. The depressed responses 
of the papillary muscle preparations from diabetic rats discussed 
above may be explained as an alteration in beta-adrenoceptor sen-
sitivity. A reduced beta-adrenoceptor sensitivity can also explain 
the bradycardia which accompanies experimental diabetes. As pre-
viously shown, diabetes reduces beta-adrenoceptor sensitivity by 
reducing beta-adrenoceptor density. The possibility of reducing beta-
adrenoceptor sensitivity by the reduction of agonist binding affinity 
needs to be reexamined. The functional differences between agonist 
and antagonist binding kinetics (Weiland~ al., 1979; 1980) suggest 
that diabetes may alter agonist binding affinity without altering 
antagonist binding affinity. Agonist-induced desensitization of 
beta-adrenoceptors may reduce the apparent agonist binding affinity 
without altering antagonist binding affinity (Tse~ al., 1978; 
Hoffman and Lefkowitz, 1980; Harden, 1983). Response is a function of 
agonist binding, complete assessment of beta-adrenoceptor sensitivity 
requires characterization of agonist binding affinity (Wessels~ al., 
1978). 
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The original hypothesis of the present study stated that diabetes 
reduces agonist affinity for beta-adrenoceptors in the rat heart. 
The recent observations by Williams~ al., 1983) that eight weeks of 
streptozotocin-induced diabetes had no effect on beta-adrenoceptor 
agonist binding lead to a re-evaluation of the hypothesis. The pre-
sent study reexamines the recent findings that diabetes does not alter 
beta-adrenoceptor drug-binding affinity using alternative experimental 
techniques. A decrease in beta-adrenoceptor number plays a major role 
in the diabetic subsensitivy to catecholamines and can help to explain 
the bradycardia which accompanies experimental diabetes in the rat; 
however, the possible role of a reduction in agonist affinity remains 
unclear. This study provides a systematic determination of beta-
adrenoceptor agonist and antagonist affinities in normal and experi-
mentally-diabetic rat atria. The use .of isolated atria allows 
characterization of both the positive ~ronotropic and positive 
inotropic effects of catecholamines. 
Several pharmacological procedures exist for the determination of 
agonist affinity. The availability of the beta-adrenoceptor antago-
nist Ro 03-7894 (1-(5-chloroacetylaminobenzfuran-2-yl)-2-isopropyl-
aminoethanol), which acts irreversibly and selectively with 
beta-adrenoceptors (Nicholson and Broadley, 1978; Rankin and Broadley, 
1982) allows pharmacological characterization by the method of partial 
irreversible receptor blockade (Furchgott and Bursztyn, 1967). The 
method of partial agonists described by Waud (1969) affords an alter-
native technique for the determination of agonist afinity for beta-
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adrenoceptors. Construction of Schild plots, using several 
concentrations of a competitive beta-adrenoceptor antagonist, allows 
calculation of antagonist affinities, expressed as pA2 values. The 
present study statistically compares agonist dissociation constants 
(!/Affinity) or antagonist pA2 (-log KB) values from control and 
diabetic rat atria tests for affinity changes produced by diabetes. 
LITERATURE REVIEW 
Induction of Diabetes 
. 
Alloxan and streptozotocin are the most extensively used agents 
for induction of diabetes because the diabetogenic dose is 1/4 to 1/5 
times the lethal dose (Grodsky ~al., 1982). The dose varies con-
siderably among species and with the age and metabolic state of the 
animal. Both alloxan and streptozotocin produce beta-cell necrosis in 
the rat (Ganda ~al., 1976). Streptozotocin appears to be more 
selective than alloxan (Rerup, 1970); the possible reason for this 
might be the high capacity of beta cells to accumulate this agent 
(Srivasta ~al., 1982). Streptozotocin models are thought to be more 
relevant to the human diabetic state than alloxan models, due to meta-
bolic profiles, enzyme concentrations, and histopathology. Alloxan-
induced diabetes is more ketotic than streptozotocin-induced diabetes 
(Mansford and Opie, 1968). 
Due to its instability, streptozotocin is dissolved in 0.1 M 
citrate buffer, pH 4.5 just prior to injection. Streptozotocin is 
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optimally stable at around pH 4 (Rerup, 1970) and its biological half-
life is about 5 minutes, which necessitates an intravenous injection. 
For induction of diabetes, streptozotocin is conventionally admi-
nistered as a single injection (Like and Rossini, 1976). Maximal ele-
vation of plasma glucose is achieved with 60 mg/kg (Ganda ~al., 
1976), but significant increases in plasma glucose occur with 40 
mg/kg. 
Pharmacological vs. Radioligand Binding Techniques for Assessing 
Receptor Characteristics 
Recent reviews (Furchgott, 1978; Tallarida 1981; 1982) compare 
the strengths and drawbacks of pharmacological and radioligand binding 
procedures. In summary, both procedures estimate drug-binding affini-
ties for a specific receptor and the rate and extent of receptor inac-
tivation by irreversible antagonists. However, only a radioligand 
yields an estimate of receptor number or density (Bmax), whereas, a 
pharmacological procedure permits evaluation of the relative effica-
cies of agonists acting upon a receptor to produce a response. 
Radioligand binding procedures require the demonstration of specific 
binding to tissue sites and no effect is measured. Thus, receptor is 
defined differently in each technique. The pharmacological definition 
of receptor has an "operational" meaning, i.e., drug-binding produces 
an effect; whereas the radioligand binding technique requires 
demonstration of a specific binding site or receptor. Typically, 
pharmacological procedures employ isolated tissue and radioligand 
techniques use membrane fractions. 
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The pA2 and the Schild Plot 
The Schild regression (Arunlakshana and Schild, 1959), theoreti-
cally, can yield the binding constant (KB) of a competitive antagonist 
for a drug receptor using pharmacological techniques. The x-intercept 
of the Schild regression (pA2) provides an estimate of the binding 
constant under certain conditions (Furchgott, 1972). The pA2 is 
important in classifying receptors (Kenakin, 1982). The pA2 is 
defined as the negative logarithm of the molar concentration of an 
antagonist which reduces the effect of a dose of agonist by half 
(Tallarida ~al., 1979). Figure a shows a Schild plot constructed 
from cumlative dose-response curves in the presence of various con-
centrations of a competitive antagonist (see figure b). 
Figure a: Theoretical Sc hjlJ Plot Depicting the 'pA2 Value 
' ~
0 
~ 
0 
- log(Antagonist Concentration) 
9 
A theoretical Schild Plot, log (DR-1) versus -log [B], consisting 
of a straight line of slope unity and an x-intercept (-log KB or pA ). 
Several antagonist concentrations [B] yield the points for drawing the 
line. 
10 
Figure b: Cumulative Dose-Response Curves of a Full Agonist Illustrating 
Competitive Antagonism 
A A 1 A' I Agonist Concentration 
As the antagonist concentration [B] increases, the dose-response 
curve shifts to the right. The degree of the shift is indicated by 
the dose ratio (DR) of A'/A. Thus, it takes a higher agonist concen-
tration, A', to produce the same effect in the presence of antagonist 
than the concentration A, producing the same effect in the absence of 
antagonist. All curves achieve the same maximum effect, since the 
antagonism is surmountable and the curves should be parallel due to 
the competitiveness of the antagonism. The dose ratios (DR), con-
verted to log (DR-1), for each antagonist concentration [B], expressed 
as -log [B] yield points for a Schild plot. 
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Based upon the occupation theory (Furchgott, 1972) stating that 
the effect produced by an agonist depends upon the concentration of 
the agonist-receptor complex, the following equation can be derived: 
[A'] - 1 =fil 
TAJ KB 
or log (DR-1) = - log KB + log [B] 
where DR (dose ratio) is defined as [A']/[A], Bis the antagonist 
concentration and KB is the equilibrium binding constant of the anta-
gonist. 
A plot of log (DR-1) versus the negative logarithm of the antago-
nist concentration (-log [B]) in molar units yields a straight line 
with a slope of 1 (Figure a). The x-intercept yields the pAz values 
or the negative logarithm of the equilibrium binding constant of the 
antagonist. 
Agonist Affinity (l/KA): Method of Partial Irreversible Receptor 
Blockade 
The method of partial irreversible receptor blockade (Furchgott 
and Bursztyn, 1967) avoids the assumption of classical receptor theory 
that the full effect requires full receptor occupancy. The method 
requires an antagonist that combines with the same receptor as the 
agonist. The antagonist, by combining irreversibly and selectively 
with the receptor, reduces the free receptor population. If a suf-
ficient number or receptors become inactivated, then the maximum 
response diminishes, based upon .the occupation theory. 
Figure c illustrates the dose-response curves obtained from an 
idealized experiment using partial irreversible receptor blockade. 
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Partial irreversible receptor blockade displaces the dose response 
curve to the right and reduces the maximum response in a dose-
dependent manner. This method requires proper washout of the antago-
nist to achieve an equilibrium receptor blockade. 
~ 
Figure c: Equal Response to a Full Agonist in the Absence and Presence 
of Irreversible Receptor Blockade 
E 
Agonist Concentration 
Curve II represents the dose-response curve for agonist after 
washout of the irreversible antagonist. Curve II does not achieve the 
maximum response of curve I (pre-antagonist). The irreversible antagonist 
displaces the dose-response curve to the right. Equiactive effects from 
the linear portion of each line E1 and E4 etc., yield pairs of agonist concentrations, (A_ ,A' 1 ), (A7 , A
1
2), etc. which produce each effect. Plotting the reciptccaI valu~s of each pair of agonist concentration, 
(1/A1,1/A' 1), etc. yields a straight-line. 
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By taking equiactive effects lying on the linear portions of both 
curves (see figure c), one obtains pairs of agonist concentrations 
corresponding to each effect; i.e., (A1, A'1), (Az, A'z), •••• (AN, 
A'N)• Plotting each pair of agonist concentrations, expressed as 
their reciprocals (l/A, l/A'), theoretically yields a straight line 
(figure d). After irreversible inactivation of a fraction of recep-
tors, a small fraction (q) of receptors remain active. Also, equal 
effects require the same amount of receptor occupancy (E 2 f(AR)). 
From these conditions, the following equation for the line obtained in 
the double reciprocal plot is derived: 
l/A 2 l/q • l/A + 1-q/q • l/KA 
where KA is the dissociation constant of the agonist. The slope 
of the line is the reciprocal value of the fraction of remaining 
receptors (q). The dissociation constant may be determined by 
subtracting one from the slope and dividing the resulting value by the 
y-intercept (see figure d). 
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Figure d: Double Reciprocal Plot of Equipotent Agonist Concentrations in 
the Absence and Presence of Irreversible Receptor Blockade 
.. 
y-int. =((1-q)/q) (l/K) 
A 
I/A' 
msJ/q 
'Illeoretical double reciprocal plot with slope of 1/q and 
y-intercept of (1-q/q)(l/KA), obtained from partial irreversible receptor 
blockade experiments. It "follows that the KA is slope-1/y-intercept. 
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Agonist Affinity (l/KA): Method of Partial Agonists 
The method of partial agonists (Waud, 1969) makes use of the 
large cardiac spare receptor capacity (Venter, 1979) and the fact that 
partial agonists require greater receptor occupancy than full ago-
nists. Irreversible antagonists make full agonists act like partial 
agonists, and thereby allow estimation of the full agonist's receptor 
affinity. Since a larger receptor occupancy is required, a partial 
agonist may or may not elicit the tissue's maximum response. 
In this method, one constructs dose-response curve for a full 
agonist followed by a dose-response curve for the partial agonist, 
after restoration of resting levels. Figure 4 shows the concentration 
of each agonist which produce equal responses yield agonist con-
centration pairs, (A1, P1) ••• (AN, PN) with A1 representing the full 
agonist concentration and P1 representing the partial agonist con-
centration from only the linear portions of each line (Thron, 1970). 
Plotting the reciprocal values of each agonist pair, (l/A, l/P), 
yields a straight-line (figure f) having the following equation: 
where A and P represents the full agonist and partial agonist 
concentration, respectively. The two terms KA and Kp represent 
equilibrium dissociation constants for the full and partial agonists. 
The value obtained by dividing the slope by the y-intercept yields the 
equilibrium dissociation constant of the partial agonist (Kp): 
slope/y-intercept eA/KA • Kp/ep 
eA I epKA 
after cancelling out like terms. 
17 
Kp 
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Figure e: Equal Response to a Full and Partial Agonist 
E 
A p 
Agonist Concentration 
Curve I represents a dose-response curve to a full agonist. 
Agonist concentrations, A , Ar., etc. produces an effect, E , E etc. 
Partial agonist concentrations, P1 , P2 etc. from curve 11
1 yi~ld the same 
effects, E1, E2 etc. 'Illus, for egch effect, there exists a pair of agonist concentrations which can produce the same effect. 
Figure f: Double Reciprocal Plot of Equipotent Agonist Concentrations Using 
Agonists with Different Efficacies 
1/P 
Equiactive agonist concentrations (Ai, Pi) yield reciprocal pairs 
(l/A1 , l/Pi) which yield the following line; 
l/A • eA/ePKA + eA/KA • ~/ep • l/P 
The quotient obtained by dividing the slope ,by the y-intercept 
yields the partial agonist dissociation constant (KP). 
20 . 
MATERIALS AND METHODS 
Animals 
Male Sprague-Dawley rats (7 weeks old) were obtained from Charles 
River Breeding Labs (Wilmington, Mass.). Unless otherwise indicated, 
all animals were supplied with food (Purina Rat Chow) and water ad 
libitum and housed under identical conditions throughout the 10-week 
experimental period. 
Experimental Grouping 
The rats were divided into three main groups, designated control 
(CT), streptozotocin-diabetic (STZ), and food restricted control (FR) • 
. . 
The CT and STZ groups were divided into eight subgroups (1-8) and the 
FR group into two subgroups (7-8) of at least 4 rats each. The food 
restricted rats received two pellets of rat chow daily. Five of the 
subgroups (1-5) were used for the study of competitive beta-
adrenoceptor blockade with each subgroup representing a different con-
centration of timolol maleate. The sixth subgroup (6) was used for 
the study of beta-adrenoceptor activation by the partial agonist, 
metaproterenol. The remaining subgroups (7-8) were used to study the 
effect of the irreversible beta-adrenoceptor antagonist, Ro 03-7894. 
The number of rats within each subgroup are shown in Table 1. 
Table 1. Experimental Grouping of Rats 
Timolol Maleate Concentration(M) Partial Agonist Irreversible Antagonist 
10-9 10-8.S 10-8 10 -7.S __ MetaEr.oterenol As.corbate Ro 03-7894 
Group '-- SubgrouE 1 2 3 4 s 6 7 8 
(CT) 6 6 6 4 6 6 4 5 
(STZ) 4 4 6 4 6 4 6 4 
(FR) - - - - - - 4 4 
This, table shows the grouping and number of rats used in the study of beta-adrenoceptors. 
CT = Age-matched controls fed ad libitum; STZ = streptozotocin-induced diabetic animals; FR 
age-matched food restricted controls fed 40 grams of rat chow daily. Subgroups 1-4 represent 
timolol concentrations used in the study of reversible antagonism. Subgroup S was used as con-
trols for both the reversible antagonism and partial agonist study. The partial agonist, 
metaproterenol, was used with animals in subgroup 6. The remaining subgroups (7-8) were used 
for the study of irreversible antagonism, ascorbate control and Ro 03-7894. 
N 
..... 
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Induction of Diabetes 
Diabetes was induced in rats with a single intravenous injection 
of streptozotocin or STZ (40 mg/kg) into a tail vein (Rerup, 1970; 
Like and Rossini, 1976; Ganda ~al, 1976). The STZ was prepared in 
0.1 M citrate buffer, pH 4.5 (40 mg/ml) immediately before injection. 
About 75% of the animals injected with STZ became diabetic and exhi-
bited glycosuria. Animals which were injected with STZ, but did not 
subsequently become diabetic, were omitted from the study. Age-
matched controls were injected with the citrate vehicle. Four to seven 
days after injection, weekly metabolism and blood pressure recordings 
were initiated. Ten weeks after injection, the animals were sacri-
ficed. 
Metabolism Studies 
Beginning one week prior to injection, all rats were placed 
singly into metabolism cages once a week for a period of 24 hours. 
The following measurements were recorded: urine output, the extent of 
glycosuria using enzymatic test strips (Tes-Tape®, Lilly) body weight, 
and food and water consumption. 
Indirect Blood Pressure and Pulse Rate Measurement 
Beginning two weeks prior to injection, systolic blood pressure 
and pulse rates were measured weekly using an indirect tail-cuff 
method. The measurements were made after warming the rat at 34°C for 
20 minutes in a temperature-controlled box. An inflatable cuff was 
placed around the base and a small bulb was placed on the distal por-
tion of the tail. The bulb was attached to a pneumatic pulse trans-
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ducer (MK III) which was coupled to an electrosphygmograph coupler 
(Narco 7211) and an E & M type 4 physiograph. Systolic arterial 
pressure was obtained by inflating the tail cuff at pressures 
exceeding 180 mm Hg, then noting the point at which the pulsations 
reappeared during slow pressure reduction. Pulse rates were recorded 
simultaneously by determining the number of pulses per centimeter at a 
set paper speed on the physiograph. The mean of at least three 
measurements was recorded for each animal. The pressure was 
calibrated at frequent intervals using a mercury column manometer. 
Isolated Atria 
Ten weeks after injection, the rats were killed by a blow to the 
head. The chest cavity was opened and the heart was rapidly removed 
and placed in oxygenated buffer at ·room temperature. A blood sa~ple 
was taken from the chest cavity for analysis of serum thyroxine and 
glucose. The blood sample was frozen in liquid nitrogen for later 
analysis. The left and right atria were surgically removed from the 
ventricles. The right atria were tied to tissue hangers by cotton 
thread and the left atria were clamped to stimulating electrodes. 
Both atria were vertically suspended in a 100 ml organ bath containing 
Krebs-Henseleit buffer (composition in llii: NaCl, 120; KCl, 5.6; 
CaCl2·6H20, 2.4; NaH2P04, 1.21; MgS04•7H20, 1.33; Na2EDTA, 0.20; 
NaHC03, 25; and glucose, 10) gassed with 5% C02 in oxygen at 37°C. 
The atria were connected by cotton thread to a tension transducer; 
Narco type A (0.1 - 3 gram sensitivity), and Narco type B (0.1 - 10 
gram sensitivity) for right and left atria, respectively. The 
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resulting tensions were recorded on an E & M type six physiograph. 
Initial diastolic resting tensions of 0.8 and 0.5 grams were applied 
to the left and the right atria, respectively. Resting tensions were 
determined from preliminary length-tension determinations. The left 
atria were driven at 2 HZ with square wave pulses (5 msec) at 1.5 
times the threshold voltage by a Narco stimulator and the right atria 
were allowed to beat spontaneously. Tension (g) and rate (bpm) 
changes were measured from the left and right atria, respectively. 
Serum Analysis 
Blood samples were thawed at room temperature and were allowed to 
clot. The clot was sedimented by centrifugation at 5000 g for 5 minu-
tes at 4°C. The supernatant (serum) was decanted for analysis of 
thyroxine and glucose. Hypothyroidism often accompanies the diabetic 
state. An AmerlexN T-4 RIA kit was used to determine serum thyroxine 
levels; the kit has a total range of 0 to 25 ug thyroxine/100 ml. 
Serum was deproteinized with equinormal amounts of barium hydroxide 
and zinc sulfate solutions prior to glucose determination. The solu-
tion fraction was obtained by centrifugation at 5000 g for 10 minutes 
and used for analysis of glucose. Glucose was determined enzymati-
cally with glucose oxidase and peroxidase (Sigma Kit No. 510). Serum 
glucose was used to estimate the degree of the diabetic state. 
Drug Addition 
Left and right atria from non-diabetic (CT) and diabetic (STZ) 
rats were allowed to stabilize for thirty minutes with frequent buffe! 
changes. The following protocol of drug administration was employed. 
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Three cumulative dose-response curves were generated consecutively per 
atrium. Each curve was obtained by adding dl-isoproterenol directly 
to the buffer, yielding concentrations ranging from lo-10 to lo-6 M, 
in O.S log molar increments (Van Rossum, 1963). The response to each 
concentration of isoproterenol was allowed to stabilize prior to the 
addition of the succeeding concentration (this stabilization period 
never exceeded 60 seconds). After the maximum responses were obained, 
the atria were washed with drug-free buffer solution, at S minute 
intervals for at least 30 minutes, to restore the tension or rate to 
resting levels prior to the generation of the subsequent curve. When 
appropriate, the third curve was generated using the partial beta-
adrenoceptor agonist dl-metaproterenol, at concentrations between lo-8 
and lo-4 M, instead of dl-isoproterenol. Only the results of the 
second and third curves were utilized, because previous studies have 
shown that the slope of the first dose-response curve is different 
from those of subsequent curves, and that the slopes of subsequent 
curves are similar (Broadley and Lumley, 1977). 
Antagonist drugs, when necessary, were added to the buffer prior 
to generating the third dose-response curve. timolol maleate was 
added 40 minutes before, and was presenc throughout the generation of 
the third dose-response curve. Ro 03-7894 (3.2 x lo-4M) was added to 
the bath for 30 minutes, then washed out with drug-free buffer for 
four hours, prior to the generation of the third dose-response curve. 
Parallel controls were exposed to an equivalent volume of the solution 
used to dissolve the antagonist, but were otherwise treated iden-
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tically. Stock solutions of isoproterenol, metaproterenol, and timo-
lol maleate were dissolved in 0.1 N HCl, and Ro 03-7894 in ascorbic 
acid solution (1 mg/ml). All drug dilutions were prepared fresh 
daily, and kept on ice. 
Resources 
Drugs: Timolol Maleate from Merck, Sharpe & Dohme 
Ro 03-7894 from Roche Products, Ltd. 
dl-Isoproterenol from Sigma Chemical Co. 
dl-Metaproterenol from Boehringer Ingelheim 
Streptozotocin from Sigma Chemical Co. 
Instruments: E & M Type Six Physiograph 
Narco Type A Tension Transducer 
Narco Type B Tension Transducer 
Narco Stimulator 
Serum 
Analysis Kits: 
Thermomix Circulation Pump and Heater 
E & M (MK III) Pneumatic Pulse Transducer 
Narco (7211) Electrosphygmyograph Coupler 
E & M Type Four Physiograph 
Serum Glucose 510 from Sigma Chemical Co. 
Amerlex T-4 RIA Kit from Amersham Corp. 
DATA ANALYSIS 
Plotting Dose-Response Curves 
Responses were measured as the total rate or contraction fre-
quency (bpm) and total developed tension (g) of the right and left 
atria, respectively, at each agonist concentration. Possible changes 
in the sensitivity of right or left atria to the agonist between the 
second and third curves which might occur in the absence of antagonist 
drugs were accounted for using parallel control atria which were not 
treated with the antagonist (Broadley and Nicholson, 1979). Mean 
.. 
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responses of untreated atria to each agonist concentration during the 
generation of the third dose-response curve were expressed as a f rac-
tion of the mean responses to the equivalent agonist concentration 
occurring during the generation of the second dose-response curve. 
These fractions were then applied as correction factors for antagonist 
treated atria. The response to each agonist concentration during the 
second dose-response curve was multipled by the appropriate correction 
factor, to yield a corrected dose-response curve. The effect of the 
antagonist on the third curve was then determined by comparison with 
the corrected second curve. 
The responses were standardized to a percentage maximum response 
scale. Increases in rate or tension above the resting levels were 
expressed as a percentage of the maximum increase. This was calcu-
lated by dividing the individual increase in rate or · tension by the 
maximum rate or tension increase and multiplying the resulting 
quotient by roo%. 
Estimations of agonist potency (EC50 values) were calculated as 
the negative log of the agonist concentration which produced half the 
maximum response. Arithmetic mean values of the EC50 are not normally 
distributed (Fleming et al., 1972), but the logarithmic values are. 
Therefore, pD2 values (-log EC50) were compared by the student's t-
test for normal and diabetic atria. 
Calculation of Antagonist Affinity by Using a Competitive Beta-
Adrenoceptor Antagonist: 
pA2 values for the antagonism of isoproterenol-induced positive 
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inotropic and positive chronotropic response by timolol maleate in 
non-diabetic (CT) and diabetic (STZ) rat .atria were calculated by the 
method of Arunlakshana and Schild (1959). Dose-response curves were 
obtained before and in the presence of one of four timolol mealeate 
concentrations (10-9, 10-8.5, 10-8, and 10-7.5M). Uncorrected respon-
ses, measured as the increase in tension or rate above resting levels 
at each isoproterenol concentration, were expressed as a percentage of 
their own maximum increase for both the second and third curves. The 
EC50 of each individual curve was then determined. 
As described above, sensitivity changes not due to the antagonist 
were corrected for by comparing the results obtained from control 
experiments receiving no antagonist. Any shift between the second and 
third curve was expressed as a mean (n=6) correction factor (CF = L 
(EC50, curve 3/EC50, curve z)ln. The individual EC50 values of the 
second curves were corrected by multiplication by the mean correction 
factor to yield a corrected EC50 value. The corrected EC50 values 
were used to obtain individual dose ratios (DR = EC50,curve 3/ 
corrected EC50,curvez). Each dose ratio was converted to log (DR-1) 
values. The mean log (DR-1) values (± S.E) were plotted against the 
negative log molar concentration of timolol maleate (-lOg B) for both 
rate and tension responses. Individual log (DR-1) and -log B points 
were used to calculate a regression line (least squares analysis). 
The values of slope, y-intercept, and x-intercept (pAz), with 95% con-
fidence limits were calculated (Tallarida, 1979). The pAz values for 
both non-diabetic and diabetic rats were compared using an unpaired 
Student's t-test. 
Estimation of AgOnist Affinity Using a Partial Beta-Adrenoceptor 
Agonist: 
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Dissociation constants (Kp) for metaproterenol were calculated 
for control (CT) and diabetic (STZ) rat atria by the method of partial 
agonists described by Waud (1969). The atria were exposed to cumula-
tive concentrations of isoproterenol twice with a washing in drug-free 
buffer after each exposure to yield two dose-response curves. A third 
dose-response curve was constructed using cumulative concentrations of 
metaproterenol. The second dose-response curve was corrected as 
described earlier (see "plotting dose-response curve"). The increases 
in rate or tension in response to each isoproterenol concentration 
were plotted as a percentage of the maximum increase. The increases 
in rate or tension in response to each metaproterenol concentration 
were plotted as a percentage of the maximum possible increase, which 
was calculated by subtracting the resting level prior to the third 
dose-response curve from the corrected second dose-response curve 
maximum total rate or tension. 
Equiactive concentrations of isoproterenol (A) and metaproterenol 
(P) obtained from the linear portion (Thron, ·1970) of each curve were 
determined. The reciprocal values for each atrium were plotted as 
1/A versus l/p to yield the following line: 
1/ A .. eA • i • l/p + eA 1 
where eA and ep correspond to relative efficacy values for 
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isoproterenol and metaproterenol, respectively. 
The dissociation constant (Kp) for metaproterenol equals the 
slope divided by the intercept, which are obtained from linear 
regression analysis. Dissociation constants for diabetic and normal 
atria were compared to an unpaired Student's t-test. 
Estimation of Agonist Affinity Using An Irreversible Beta-Adrenoceptor 
Antagonist: 
Dissociation constants (KA) for isoproterenol were calculated for 
normal (CT), diabetic (STZ) and food restricted (FR) rat atria by the 
method of irreversible antagonism derived by Furchgott and Bursztyn 
(1967). Individual pre- (2nd curve) and post-antagonist (3rd curve) 
dose-response curves were plotted as described earlier (see "plotting 
dose-response curves") for total responses. The increase in rate and 
tension above the resting levels prior to each dose-response curve 
were plotted as a percentage of the corrected second curve maximum 
increase (the maximum possible increase). This method avoids possible 
misinterpretation arising from any change in the resting levels 
induced by the antagonist. 
Equiactive molar concentrations of isoproterenol obtained before 
[A] and after washout of antagonist [A'] were determined from the 
linear portion of the plot of % corrected second curve maximum 
response versus the negative log concentration (M) of isoproterenol. 
The mean reciprocal(± S.E.) values were plotted as l/A versus 1/A'. 
The following equation was used to determine dissociation constants: 
1 I A = .!..:.9.. • 1 
q KA 
+ 1 
q 
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l/A' 
where q is the fraction of remaining receptors unoccupied by Ro 
03-7894. 
Using linear regression analysis, the mean dissociation constants 
(KA) and fraction of active receptors remaining (q) with 95% con-
fidence limits were calculated as follows: 
KA ,,.. [Slope- I) 
intercept 
, q .. __ l_ 
slope 
Because constants for normal, diabetic, and food restricted rat 
atria were compared using one way analysis of variance (Daniel, 1978). 
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RESULTS 
The Streptozotocin Diabetic Model* 
Differences between streptozotocin-induced diabetic food-
restricted, and control animals are shown in Table 2. The STZ-induced 
diabetic rats exhibited reduced body weight, as did the food-
restricted rats though to a lesser extent, when compared to age-
matched control rats. Polyuria, hyperglycemia, and glycosuria 
accompanied the diabetic state, as well as, polydipsia and polyphagia 
(data not shown). The diabetic state significantly lowered serum 
thyroxine levels compared to the food-restricted group. Normal 
thyroxine levels range from 3-4 ug/dl (Fein~ al., 1980). Diabetes 
produced a slight hypertension and bradycardia. There were no signi-
ficant differences between the potencies (pD2 values) for isoprotere-
nol from control, food-restricted, and diabetic atria. 
Figures 1-3 depict results from weekly monitoring of heart rate, 
blood pressure, and body weight following the injection of strep-
tozotocin or citrate vehicle. Diabete~ produces significant changes 
in all three (bradycardia, hypertension, and reduced body weight) 
within three weeks after injection of streptozotocin and these changes 
persist throughout the ten week experimental period. 
* "Diabetes" will be used to describe the diabetic condition 
induced by streptozotocin injection, with the implicit recognition 
that chemically induced diabetes may differ in some respects from the 
true diabetic state. 
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Table 2: Characteristics of Diabetic and Control Groups 
CT STZ FR 
BW 526 ± 16 413 ± 10* 464 ± 10* 
(n=43) (n=37) (n=9) 
Glu 239 ± 14 651 ± 37* 279 ± 48* 
(n=20) (n=21) (n=5) 
T-4 1.22 ± 0.11** 2.41 ± 0.47 
(n=38) (n=8) 
Urine 0.03 ± 0.01 o.53 ± 0.05* 0.05 ± 0.01 
(n=-23) (n=12) (n=9) 
Urine Glu 0 2 +* 0 
(n=23) (n=12) (n=9) 
BP 136 ± 3 148 ± 2* 
(n=23) (n=12) 
HR 376 ± 9 327 ± 11* 
(n=23) (n=12) 
RA 8.37 ± 0.92 8.28 ± 0.58 8.37 ± 0.26 
pD2 (n=43) (n=-37) (n=9) 
Iso LA 8.51 ± 0.53 8.62 ± 0.44 8.15 ± 0.22 
(n=43) (n=37) (n=9) 
Values represent mean ± 95% confidence intervals. Numbers in parentheses 
represent the sample size. Asterisk (*) means that the value is signi-
ficantly different (P (0.05) than the control value; the double 
asterisks means that the value is significantly different than the food 
restricted value. 
Abbreviations 
CT = Age-matched controls fed ad libitum; STZ = Streptozotocin-induced 
diabetes, 10 weeks after the induction of diabetes; FR = Age-matched 
controls on a food-restricted diet; BW = Body weight (grams; Glu = Serum 
glucose levels (mg/ml); T-4 = Serum thyroxine levels (µg/dl); 
Urine =Urine output (ml/g BW); Urine Glu =Urine glucose levels (%); 
BP = Systolic blood pressure (mm Hg); HR= Heart rate (beats per 
minute); pD2 =-log EC50 of the molar concentration of isoproterenol 
producing half the maximal response; RA = Right atria; LA = Left atria. 
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Figure 1: Effect of SI'Z-Induced Diabetes on Heart Rate 
2 3 5 6 7 8 
Time(weeks) after streptozotocin or citrate injection 
Heart rates (± S.E.M.) taken weekly during the 10 week 
experimental period from control ( e ) and diabetic ( • ) rats. A typical 
age-dependent bradycardia developnent occurs in both groups with the diabetic 
rats showing significant reductions within three weeks after injection of 
streptozotocin. Asterisks represents significant differences from control 
at P ~ 0.05. Nunbers in parentheses represent sample size. Time (weeks) 
after streptozotocin or citrate vehicle lies on the abscissa. Heart rate 
expressed as beats per minute (bpn) is shown on the ordinate. 
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Figure 2: Effect of srz-Induced Diabetes on Systolic Blood Pressure 
2 3 4 s 6 7 8 
Time(weeks) after streptozotocin or c itrate injection 
'Ihe mean systolic blood pressure (± S.E.M) taken 
weekly during the JO week experimental period from control( ~ ) and 
diabetic ( II ) rat. A typical age-dependent elevation in blood 
35 
pressure occurs in both groups with the diabetic rats showing significant 
elevations above control within two weeks after the injection of streptozo-
tocin. Asterisks represent significant differences from control at P < 0.05. 
Numbers i« parentheses represent sample size. Time (weeks) after strep-
tozotocin or citrate vehicle injection lies on the abscissa. Systolic 
blood pressure (lllTI Hg) is shown on the ordinate. 
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Figure 3: Effect of STZ-lnduced Diabetes and of Food Restriction on Body Weight 
BOdy weight (± S.E.M.) taken weekly for twelve 
weeks. Auin~ls received streptozotocin (STZ) or citrate vehicle (CIT) 
during the second week. Initiation of the food restriction regimen 
occurred during the second week. Asterisks represent significant dif-
ferences from control at P < O.OS. Numbers in parentheses represent 
sample size. Time (weeks) Ties on the abscissa. Body weight (grams) 
is shown on the ordinate. • = control; 8 = diabetic; .A. = food 
restriction. 
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Competitive Antagonism of the Responses to Isoproterenol by Timolol 
Maleate 
Figures 4 a-d depict the mean rate and tension dose-response cur-
ves to isoproterenol in the presence of increasing concentrations of 
timolol maleate. Increasing concentrations of timolol maleate (10-9, 
10-8.5, lo-8, and 10-7.5 M) displaced the cumulative dose-response 
curves (control and diabetic) to isoproterenol to the right in 
parallel fashion without significantly (P ~ 0.05) depressing the 
maximum response. Diabetic right atria (figure 4c) had lower resting 
rates (P ~ 0.001) than control right atria (figure 4a), but the maxi-
mum rates were not different. Diabetes did not significantly affect 
the resting or maximum developed tension of left atria (figures 4b and 
d). Figures 5 a-d show the mean increase in rate and tension above 
resting levels, expressed as a percentage of the maximum possible 
increase (determined by subtracting the resting level from the maximum 
response obtained during the pre-antagonist dose-response curve), for 
control and diabetic atria. The dose-response curves for isoprotere-
nol exhibit parallel shifts to the right of the curve generated in the 
absence of timolol maleate in a timolol maleate concentration-
dependent manner. 
Figures 6a and b depict Schild plots constructed from the mean 
log (DR-1) values shown in Table 9 (see appendix) for right and left 
atria, respectively. Regression analysis of the individual log (DR-1) 
values for the appropriate timolol maleate concentration yields the 
pAz value and slope for each line. Table 3 shows the mean pAz values 
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(± 95% confidence interval) and slopes (± 95% confidence interval) 
for each Schild plot shown in figures 6a and b. Diabetes had no 
effect on either the slope of the Schild plot or the estimate of anta-
gonist binding affinity (pAz) in either right or left atria. The slo~ 
pes of the individual Schild plots do not vary significantly from 
unity. 
a. 
b. 
Figure 4 a-d: Effect of Tirnolol Maleate on the Absolute Response of Non-
Diabetic and Diabetic Rat Atria to Isoproterenol 
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Figure 4 a-d: Effect of Timolol Maleate on the Absolute Response of 
Non-Diabetic and Diabetic Rat Atria to Isoproterenol 
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Mean cumulative dose-response curves (± S.E.M.) to dl-isopro-
terenol in the presence of various concentrations of timolol maleate 
from control (a and b) and diabetic (c and d) rat atria. The curves 
represent the mean rate (± E.E.M.) and tension (± S.E.M.) response at 
each isoproterenol concentration. The mean diabetic resting rate (c) 
is significantly (P <0.001) lower than the mean control resting rate 
(a). A thirty minute incubation period without or with timolol 
maleate preceded the generation of each curve. The concentrations of 
timolol maleate: (•) no timolol maleate present, (o) lo-9 M, (•) 
10-8.S M, ( D ) lo-8 M, and (A) lo-7 .S M. Numbers in parentheses 
represent the sample size • 
. . 
Figure 5 a-d: Effect of Timolol Maleate on the Relative Response of 
Non-Diabetic and Diabetic Rat Atria to Isoproterenol 
Mean cumulative dose-response curves (± S.E.M.) to dl-isopro-
terenol in the presence of various concentrations of timolol maleate 
from control (a and b) and diabetic (c and d) rat atria. The curves 
represent the mean increase in rate (a and c) and tension (b and d) 
above the resting levels plotted as a percentage of the maximum 
increase for each isoproterenol concentration. Increasing timolol 
maleate concentrations shift the dose-response curve to isoproterenol 
further to the right without depressing the maximum response. The 
concentrations of timolol maleate are: (•) no timolol maleate pre-
sent, (o) 10-9 M, (•) lo-8.S M, (D) lo-8 M, and(&) lo-7.S M. 
Numbers in parentheses represent the sample size. 
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Figure 5 a-d: Effect of Timolol Maleate on the Re'lative Response of 
Non-Diabetic and Diabetic Rat Atria to Isoproterenol 
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Effect of Diabetes on the Schild Plots of Rat Atrial Responses to 
Isoproterenol in the Presence of Various Concentrations of 
Timolol Maleate 
J 
Right Atria 
I 
(n a 18 
9.0 · 8.s a.o 1.s 
- log(Timolol Maleate) (M.) 
Schild plots from control ( e ) and diabetic( • ) rat atria, obtained 
by plotting the mean log(DR-1) values (± S. E.M. ) from tables 3a and 3b versus 
the negative logarithm of the timolol maleate concentration(M). Figure 6a 
represents the right atria and figure 6b represents the left atria. Re-
gression analysis of the Schild plots is depicted in table 4. Numbers in 
parentheses represen t the sample size . 
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Figure 6 a-~ Effect of Diabetes on the Schild Plots of Rat Atrial Responses t.o 
I~oproterenol in the Presence of Various Concentrations of 
TllllOlol Maleate 
a: 
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- log(Timolol Haleate) (H.) 
Schild plots from control ( e ) and diabetic ( • ) rat atria, obtained 
by plotting the mean log(DR-1) values (± S.E.M.) from tables 3a and Jb versus 
the negative logarithm of the timolol maleate concentration(M). Figure 6a 
represents the right atria and figure 6b represents the left atria. Re-
gression analysis of the Schild plots is depicted in table 4. Numbers in 
rxH·entheses represent the sample size . 
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Table 3: Schild Plot Analys i s 
Right Atria Left Atria 
pA2 m a_ m 
CT (n=22) 9.13 ± 0.09 1.16 ± 0.18 8 .9S ± 0.03 1.18 ± 0 .2S 
STZ (n=l8) 8.98 ± 0.12 0.94 ± 0.21 9 .14 ± 0.21 1.02 ± 0.40 
Mean pA2 values (± 9S% confidence interval) of right and left 
atria from control and diabetic rat atria. No significant differences 
(P > O.OS) exist between the pA2 values from control and diabetic 
atria. The mean slopes (± 9S% confidence interval) do not differ from 
unity. The number in parentheses represent the sample size. 
Irreversible Antagonism of the Responses to Isoproterenol by 
Ro 03-7894 
.. 
Ro 03-7894 (3.24 x lo-4 M) is used as an irreversible beta-
adrenoceptor antagonist, and displaces the dose-response curves to 
isoproterenol to the right and reduces the maximum response (Nicholson 
and Broadley, 1977). Figures 7 a-f depict the mean dose-response cur-
ves, expressed as a percentage of the maximum possible increase, for 
rate (a,c,e) and tension (b,d,f) from control (a and b), food 
restricted (c and d), and diabetic (e and f) atria. Ro 03-7894 signi-
ficantly reduced the resting rates and tensions (P ,S. O.OS) and reduced 
the maximum rate and tension responses of rat atria to isoproterenol 
(Table 4). Neither diabetes nor food restriction significantly 
altered the effects of Ro 03-7894 rat atrial dissociation constants 
for isoproterenol (Table 4). Therefore, neither diabetes nor food 
restriction alters beta-adrenoceptor agonist binding affinity. The 
fraction of unoccupied receptors (q) were not significantly different 
(P > O.OS) between experimental groups, but exhibited a high degree of 
variability (Table 4). 
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Table 4: Antagonism by Ro 03-7894 and the Effect of Diabetes on the 
Dissociation Constants for Isoproterenol 
Group % Max KA (nM) 
.9.. 
Ri~ht Atria 
CT (n=6) 60.8 ± 5.0 18.2 ± 15.4 .095 ± .030 
STZ (n=4) 67.5 ± 7.6 15.3 ± 7.8 .114 ± .051 
FR (n=4) 56.0 ± 5.5 17.3 ± 5.4 .021 ± .004 
Left Atria 
CT (n=6) 33.8 ± 7.4 16.9 ± 5.3 .057 ± .026 
STZ (n=4) 70.5 ± 12.0 26.8 ± 12.2 .202 ± .090 
FR (n=4) 40.0 ± 4.0 10.7 ± 3.5 .117 ± .023 
Mean dissociation constants (± S.E.M.) for isoproterenol of car-
diac beta-adrenoceptors. No significant differences (P >0.05) exist 
between dissociation constants from control, food-restricted, and 
diabetic atria. The fraction of unoccupied receptors (q) within 
experimental groups are not significantly different (P >0.05). The 
post-antagonist maximum responses (% max) are significantly (P (0.05) 
reduced from the maximum possible response. Numbers in parentheses 
represent sample size. 
a . 
b. 
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Figure 7 a-f: Effect of Ro 03-7894 on the Relative Response of Non-Diabetic, 
Food Restricted, and Diabetic Rat Atria to Isoproterenol. 
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Figure 7 a-f: Effect of Ro 03-7894 on the Relative Response of 
Non-Diabetic, Food-Restricted, and Diabetic Rat Atria 
to Isoproterenol 
Mean dose-response curves (± S.E.M.) to isoproterenol in the 
absence (solid points) and presence (open points) of 3.24 x io-4 M 
Ro 03-7894, after a 30 minute incubation period followed by a 4 hour 
washout period. The presence of Ro 03-7894 displaces the dose-
response curve to the right and reduces the maximum response. Figures 
a,c,e, represent the positive chronotropic response and figures b,d,f 
represent the positive inotropic response to isoproterenol. Pre-
antagonist curves were corrected from controls as described in text. 
• = control animals, • = diabetic animals, & = food-restricted ani-
mals. Numbers in parentheses represent the sample size. 
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Diabetic and Non-Diabetic Atrial Responsiveness to Isoproterenol and 
to Metaproterenol 
Metaproterenol produces parallel dose-response curves shifted to 
the right of dose-response curves produced with isoproterenol. 
Figures 8 a-d depict the mean dose-response curves obtained with 
isoproterenol and then with metaproterenol producing the same maximum 
response (Pi 0.05), but requiring higher concentrations to produce 
the maximum response. 
Figure 8 a-d : Relative Response of Non-Diabetic and Diabetic Rat 
Atria to a Full (Isoproterenol) and Partial 
(Metaproterenol) Agonist. 
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Mean cumulative dose-response curves (± S.E.M.) to isoproterenol 
(solid symbols) and metaproterenol (open symbols) from control (a and 
b) and diabetic (c and d) atria. The lines represent the mean 
increase in rate (a and c) and tension (band d), plotted as a percen-
tage of the maximum possible increase. The mean resting levels are 
the same (P > 0.05) for the isoproterenol and metaproterenol. No 
significant reduction (P > 0.05) in the maximum responses occur when 
metaproterenol is the agonist. Table 6 contains the EC50 value for 
each curve. Numbers in parentheses denote sample size • 
. . 
a. 
b. 
Figure 8 a-d: Rela t ive Response of Non - Diabetic and Diabetic Rat Atria . to 
a Full (Isoproterenol) and Partial (Me taproterenol ) Agonis t. 
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The mean EC50 values of isoproterenol and metaproterenol for left 
and right atria are compared in Table 5. The EC50 values of metapro-
terenol are one hundred-fold higher than those of isoproterenol. 
Table 5: Comparison of Agonist Potencies (EC50 Values) between 
Isoproterenol and Metaproterenol for the Positive 
Chronotropic and Positive Inotropic Response for Non-
Diabetic and Diabetic Rat Atria 
Right Atria 
Iso2roterenol Meta2roterenol 
CT ~n=S~ (3.37 ± 0.6l)x10-§ (2.72 ± o.06)x10-j STZ n•4 3.77 ± 0.10 x10- 2.70 ± a.so x10-
Left Atria 
Isoproterenol Metaproterenol 
CT ~n=S~ [3.25 ± o.s11x10-§ [4.36 ± 0.43]x10-7 STZ n•4 8.20 ± 1.21 x10- [S.33 ± l.OO]xl0-7 
Mean EC50 values (± S.E.M.) of isoproterenol and metaproterenol, 
obtained from control and diabetic atria. Isoproterenol is about one 
hundred times more potent than metaproterenol. EC50 values from 
diabetic atria do not differ significantly (P > 0.05) from control 
atria. Numbers in parentheses denote sample size. 
Individual experiments yielded pairs of agonist concentrations 
which produce the same rate or tension response. Plotting the 
reciprocals of each pair as l/[isoproterenol] versus 
l/[metaproterenol] for each experiment yields straight-lines. 
Regression analysis of these lines provides values for the slope, y-
intercept, and correlation coefficient. The quotient of the slope 
divided by the y-intercept equals the dissociation constant for 
metaproterenol. Table 6 contains dissociation constants for metapro-
terenol from control and diabetic atria. No significant differences 
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(P > 0.05) were observed between control and diabetic atria. Diabetes 
does not alter metaproterenol binding affinity. 
Table 6: Effect of Diabetes on the Dissociation Constants for 
Metaproterenol 
IC (µM) 
-11eta 
Right Atria Left Atria 
CT (n=5) 5.06 ± 3.24 0.50 ± 0.14 
STZ (n=4) 5.20 ± 2.55 1.55 ± 1.49 
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Mean dissociation constants (± S.E.M.) for metaproterenol binding 
to beta-adrenoceptors from control and diabetic atria. No significant 
differences (P >0.05) exist between dissociation constants from right 
or left atria. Numbers in parentheses denote sample size. 
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DISCUSSION 
The results of the present study did not support the original 
hypothesis that diabetes reduces beta-adrenoceptor agonist binding 
affinity in rat atria. These findings are in agreement with radioli-
gand binding studies recently reported by Ingebretson ~al. (1983) 
and Williams~ al. (1983), showing that neither acute nor chronic 
diabetes affected cardiac beta-adrenoceptor binding curves. 
STZ-induced diabetes did not alter the estimated dissociation 
constants for isoproterenol or metaproterenol in the present study. 
The values for the dissociation constants for isoproterenol obtained 
in the present study agree closely with those reported for guinea pig 
atria (Table 7) and those of Williams~ al. (1983), using control 
(51 ± 15 nM), food restricted (70 ± 11 nM), and STZ-induced diabetic 
(78 ± 24 nM) rat hearts. The value for the dissociation constants for 
metaproterenol closely correspond with published values using guinea• 
pig atria and different pharmacological techniques (Table 8). 
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Table 7: Dissociation Constants for Isoproterenol (Guinea Pig Atria) 
~so (nM) 
Right Atria Left Atria Source 
37.7 ± 14.5 28.0 ± 6.9 Broadley and Williams, 1982, 1983 
(n=5) (n=8) 
a. 90.7 ± 36.0 84.7 ± 14.0 Broadley and McNeill, 1983 
(n=9) (n=9) 
b. 29.0 ± 13.0 23.0 ± 7.0 
(n=4) (n=4) 
c. 38.0 ± 18.0 24.0 ± 23.0 Broadley and Nicholson, 1980 
(na4) (n:s4) 
Kiso values are the means ± S.E. mean calculated through the use 
of irreversible receptor blockade by Ro 03-7894, (a) 7.6 x lo-4 M, 
(b) 6.4 x lo-4 M, or (c) 3.24 x lo-4 M with a 3 hour washout period. 
Numbers in parentheses denote sample size. 
Table 8: Dissociation Constants for Metaproterenol (Guinea Pig Atria) 
K. (µM) 
-Neta 
Right Atria 
8.4 ± 2.5 
(n=6) 
5.4 ± 2.1 
(n=6) 
4.2 ± 2.0* 
(n=4) 
10.0 ± 2.2 
(n=4) 
Left Atria 
4.3 ± 1.3 
(n=4) 
7.6 ± 2.9 
(n=8) 
14.7 ± 8.3* 
(n=4) 
2.4 ± 1.3 
(n=4) 
Source 
Broadley and Williams, 1982, 1983 
Williams and Broadley, 1983 
Broadley and Nicholson, 1980 
KMeta values are the means ± S.E. mean calculated through the use 
of irreversible receptor blockade by Ro 03-7894 (7.6 x lo-4 M) with a 
3 hour washout period. Asterisks signify the use of functional anta-
gonism with carbachol to calculate the dissociation constant. Numbers 
in parentheses denote sample size. 
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Values for dissociation constants have a large variability 
(Broadley and Nicholson, 1978). This variability reduces the sen-
sitivity of statistical tests in distinguishing differences between 
dissociation constants. The magnitude of the variability in the pre-
sent study is similar to those reported in the studies cited in Table 
8. 
The estimations of the fraction of unoccupied receptors (q) 
varied, which limits the ability to detect changes in beta-
adrenoceptor number. There were no significant differences between 
any of the estimates of the fraction of unoccupied receptors. 
Furthermore, no specific trend in the estimates occurs: for right 
atria, the food restricted group had the lowest estimates (0.02), but 
for left atria, the control group had the lowest estimates (0.057). 
The irreversible antagonist, theoretically, inactivates the same 
number of beta-adrenoceptors and a reduction in beta-adrenoceptor 
number would be reflected by lower estimates of the fraction of unoc-
cupied receptors. If diabetes does reduce beta-adrenoceptor number, 
then the estimations of the fraction of unoccupied receptors in diabe-
tic atria should be lower than those in control atria. However, 
atrial size can influence the estimation of the fraction of unoccupied 
beta-adrenoceptors, since a larger tissue will contain greater amounts 
of beta-adrenoceptors, and atrial size was an uncontrolled variable. 
The variations in atrial size limits the usefulness of the estimation 
of the fraction of unoccupied receptors. 
Diabetes does not alter antagonist binding affinity of cardiac 
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beta-adrenoceptors. Several radioligand binding studies (Savarese and 
Berkowitz, 1980; Ingebretson ~al., 1981; Heyliger~ al., 1982) 
demonstrate that chronic diabetes had no effect of [H3]-DHA binding 
affinity in · rat ventricular tissues. The present study confirms by 
alternative methodology that antagonist binding affinity of cardiac 
beta-adrenoceptors is not affected by diabetes. The pA2 values for 
timolol maleate from control and diabetic atria were not significantly 
different from each other (Table 3). The estimates of the pA2 values 
are consistent with those found by other investigators (Dreyer and 
Offermeier, 1980). The pA2 value equals the negative logarithm of the 
antagonist's dissociation constant when the slope of the Schild plot 
is unity (Tallarida ~ al., 1979). None of the slopes of the Schild 
plots differed significantly from each other. Thus, the antagonist 
binding affinities are the ·same in control and diabetic atria. 
Diabetes is a heterogenous disease state; other complications 
such as hypothyroidism (Fein~ al • ...L 1980; Pittman~ al., 1981·; 
Penpargkul ~al., 1981; Malhorta ~al., 1981), hypertension 
(Christlieb, 1973; Igarashi ~al., 1978; Kawashima et al., 1978; 
Factor~ al., 1981; Sasaki and Bunag, 1982; Hayashi et al., 1983) or 
hypotension (Pfaffman, 1980; Jackson and Carrier, 1981; 1983), brady-
cardia (Savarese and Berkowitz, 1980) may accompany the diabetic 
state. In the present study, streptozotocin produced a diabetic state 
characterized by glycosuria, polyuria, polyphagia, polydipsia, and 
reduced body weight. Bradycardia and a slight hypertensive effect 
accompanied the diabetic condition. The diabetic rats exhibited 
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decreased serum thyroxine levels (hypothyrodism) and increased serum 
glucose levels (hyperglycemia). 
The presence of other disease states suggests that alterations in 
the diabetic myocardium may not have a single underlying cause-and-
effect relationship, but instead may be due to a multiplicity of fac-
tors. It appears highly unlikely that streptozotocin itself could 
have produced the reductions in beta-adrenoceptor number. 
Streptozotocin is void of cardiotonic effects at a tissue and sub-
cellular level (Fein .!:E. al., 1980; 1981). However, hypothyroid ani-
mals have been shown to contain a decreased number of cardiac 
beta-adrenoceptors with alterations in antagonist (DHA) binding affi-
nity (Ciaraldi .!:E. al., 1977; Mcconnaughey .!:E. al., 1979; Chang .!:E. al., 
1982). Ischac .!:E. al. (1983) found that hypothyroidism had not effect 
on agonist potency (pAz), produced bradycardia, and had no effect on 
maximum responses to isoproterenol. Furthermore, in general, hyper-
tension can cause a reduction in beta-adrenoceptor number without 
altering [H3]-DHA binding affinity (Williams .!:E. al., 1977; Woodcock .!:E. 
al., 1979). Because diabetes reduces both alpha- and beta-
adrenoceptor density and hypothyroidism increases alpha-adrenoceptor 
density, Williams .!:E. al. (1983) discounts hypothyroidism as the pri-
mary cause of the reduction in beta-adrenoceptor density seen in 
diabetes. Furthermore, Williams et. al. (1983) found that diabetes 
had no effect on muscarinic receptor number which suggests that 
alterations in adrenergic receptors are specific. Fein .!:E. al. (1980) 
considers it unlikely that hypothyroidism produced the altered mecha-
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nics exhibited by diabetic papillary muscle because of the lack of 
correlation between the free T4 index and the altered mechanical pro-
perties. Bhalla~ al. (1980) found no difference in beta-
adrenoceptor number between control and spontaneously hypertensive 
rats, instead they found a reduced affinity of beta-adrenoceptors for 
isoproterenol. The altered metabolic status of diabetic rats may also 
produce changes in beta-adrenoceptor sensitivity. Increased plasma 
lipid content can reduce cardiac beta-adrenoceptor number without 
affecting antagonist binding affinity (Wince and Rutledge, 1981). 
Certain cardiac disease states such as ischaemia (Feuvray ~al., 
1979) and heart failure (Bristow~ al., 1982) have been associated 
with a reduction in beta-adrenoceptor number without alterations in 
[H3]-DHA binding affinity. It has already been noted that diabetics 
have a higher incidence of mortality from heart disease than the non-
diabetic population (Kannel, 1979). Ischaemia and heart failure are 
often the end results of heart disease. Thus, diabetes may predispose 
the heart to congestive heart failure in part by reducing beta-
adrenoceptor number without altering affinity. 
Food restriction does not reproduce the cardiac alterations which 
occur with diabetes (Fein~ al., 1980; Penpargkul ~al., 1981; 
Malhorta ~al., 1981). The present study shows that caloric depriva-
tion induced by restricting food intake did not alter the dissociation 
constants for isoproterenol. Williams ~al. (1983) also demonstrated 
that caloric deprivation did not produce the alterations in beta-
adrenoceptors that occur in the diabetic state. 
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In summary, the present study confirms that chronic diabetes does 
not affect cardiac beta-adrenoceptor binding affinities for agonists 
or antagonists. Diabetes lowered the basal heart rate, but had no 
affect on the maximum chronotropic responses to isoproterenol or 
metaproterenol. In addition, diabetes had no affect on agonist poten-
cies (EC50) for positive chronotropic and positive inotropic respon-
ses. The methodology examined the maximum response and receptor 
binding characteristics and did not quantitate the time course of the 
response. The reduced responsiveness to catecholamines in vivo may 
result from a slower formation of agonist-receptor complexes due to 
the reduction in beta-adrenoceptor number which has been demonstrated 
by radioligand techniques (pharmacological techniques used in the pre-
sent study cannot quantitate receptor number). Thus, chronic diabetes 
does not alter beta-adrenoceptor-drug binding characteristics, but may 
influence the effect of drug-receptor binding. 
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APPENDIX 
Table 9 contains the mean EC50 values, obtained from corrected 
pre-antagonist and post-antagonist dose-response curves to isoprotere-
nol in the presence of different timolol maleate concentrations, and 
the mean values of the logarithm (dose ratio minus one (± S.E.M.)), 
obtained from the individual dose ratios from each set of atria. The 
table also includes the timolol maleate concentration (M) present 
during the generation of the post-antagonist curve. 
Table 9: 
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Schild Plot Points from STZ-induced Diabetic and Normal 
Rat Atria 
Mean EC50 values from corrected pre-antogonist dose-response cur-
ves to isoproterenol (see "Plotting Dose-Response Curves") and from 
post-antagonist dose-response curves to isoproterenol for each con-
centration of timolol maleate (M) for right and left atria. Corrected 
pre-antogonist and post-antogonist EC50 values yield a dose ratio 
(DR) for each timolol maleate concentration, which is converted to the 
log (DR-1) value. The table shows the mean log (DR-1) values 
(±S.E.M.), which represent the ordinate values for the Schild plot. 
The values for both control (CT) and diabetic (STZ) atria are shown. 
Numbers in parentheses denotes the sample size • 
. . 
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Table 9: Schild Plot Points from STZ-induced Diabetic and Normal 
Rat Atria 
Right Atria 
CT 
STZ 
Timolol Maleate 
Concentration (M) 
lo-9 (n=6) 
lo-8.5 (n .. 6) 
lo-8 (n ... 6) 
lo-7.5 (n:s6) 
lo-9 (n=4) 
lo-8.5 (n=4) 
lo-8 (n•4) 
lo-7.5 (n--4) 
Left Atria 
CT 
lo-9 (n,.6) 
lo-8.5 (n ... 6) 
lo-8 (n .. 6) 
lo-7.5 (n=6) 
Mean EC50 (nM) 
Corr. Pre-Antag. 
Curve 
2.88 
1. 79 
2.93 
1.61 
3.48 
2.85 
5.23 
2.12 
8.36 
10.3 
9.64 
4.94 
Mean EC50 (nM) 
Post-antag. 
Curve 
5.89 
10.6 
57.4 
152 
6.55 
9.04 
40.3 
74.3 
11.3 
36.1 
137 
377 
Mean log 
(DR-1) 
0.20 ± 0.07 
0.73 ± 0.09 
1.21 ± 0.10 
2 .oo ± 0.07 
0.09 ± 0.08 
0.36 ± 0.18 
0.84 ± 0.06 
1.51 ± 0.05 
0 .08 ± 0.08 
0.35 ± 0.13 
1.07 ± 0.06 
1.86 ± 0.04 
----------~------------------------------------------------------
STZ 
lo-9 (n .. 4) 
lo-8.5 (n=4) 
lo-8 (n .. 4) 
lo-7.5 (n=4) 
7 .oo 
4.36 
6.46 
5.12 
8.52 0.13 ± 0.07 
32.4 0.65 ± 0.22 
151 1.22± 0.15 
576 1.62 ± 0 .36 
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